Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases (August 31, 2026 ) by Eli Lilly and Company Merida’s antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile

Colossal AI spinoff hits $3.8 billion valuation, targets aging with first model (August 20, 2026 ) by Sasha Richie Astromech just announced new funding to develop artificial intelligence that can predict biological outcomes. Astromech, an artificial intelligence venture gestated at Dallas’ resident sci-fi startup, secured $20 million in new funding at a $3.8 billion valuation, the company announced Thursday. Founded